Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020109978 - LPL-GPIHBP1 FUSION POLYPEPTIDES

Publication Number WO/2020/109978
Publication Date 04.06.2020
International Application No. PCT/IB2019/060140
International Filing Date 25.11.2019
IPC
C07K 14/705 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
C12N 9/20 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14Hydrolases (3.)
16acting on ester bonds (3.1)
18Carboxylic ester hydrolases
20Triglyceride splitting, e.g. by means of lipase
A61K 38/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61P 3/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
06Antihyperlipidemics
C07K 14/705
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
C07K 2319/35
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2319Fusion polypeptide
35containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
C12N 9/20
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes; Proenzymes; Compositions thereof
14Hydrolases (3)
16acting on ester bonds (3.1)
18Carboxylic ester hydrolases ; (3.1.1)
20Triglyceride splitting, e.g. by means of lipase
Applicants
  • NOVARTIS AG [CH]/[CH]
Inventors
  • GAO, Jiaping
  • NIMONKAR, Amitabh
  • TRAUGER, John
  • VOZNESENSKY, Andrei Igorevich
  • WELDON, Stephen Craig
Agents
  • NOVARTIS AG
Priority Data
62/771,35926.11.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) LPL-GPIHBP1 FUSION POLYPEPTIDES
(FR) POLYPEPTIDES DE FUSION DE LPL-GPIHBP1
Abstract
(EN)
This disclosure relates to fusion polypeptides comprising lipoprotein lipase (LPL) and glycosylphosphatidylinositol-anchored High Density Lipoprotein-binding protein 1 (GPIHBP1). The disclosure also relates to uses of such fusion polypeptides in treating disease such as familial chylomicronemia syndrome (FCS).
(FR)
La présente invention concerne des polypeptides de fusion comprenant une lipoprotéine lipase (LPL) et une protéine 1 de liaison à la lipoprotéine haute densité ancrée par glycosylphosphatidylinositol (GPIHBP1). L'invention concerne également des utilisations de ces polypeptides de fusion dans le traitement d'une maladie telle que le syndrome chylomicronémie familial (FCS).
Latest bibliographic data on file with the International Bureau